Table 2.
Results of studies in Iran
| Study | Case Group | Control Group | Method | Association of high-risk HPV with breast cancer |
|---|---|---|---|---|
| Ahangar et al. ( 29 ) | 22/65 (33.8%) | 0/65 | Nested PCR | No (low-risk HPV detected) |
| Sigaroudi et al. ( 23 ) | 16/79 (25.9%) | 1/51 | Nested PCR | Yes (predominantly high-risk types) |
| Manzouri et al. ( 27 ) | 10/55 (18.18%) | 7/51(12.72%) | PCR | No |
| Alavi et al. ( 24 ) | 24/50 (48%) | 0/29 | PCR | Yes |
| Rassi et al. ( 26 ) | 52/150 (34.66%) | ------ | Multiplex PCR | Yes (types16 and 18) |
| Salehpour et al. ( 34 ) | 54/206 (26.2%) | ------- | PCR | No (low-risk HPV detected) |
| Doosti et al. ( 32 ) | 20/87 (22.9%) | 0/84 | Nested PCR | No (low-risk HPV detected) |
| Tahmasebi Fard ( 31 ) | 0/65 | 3/53 | PCR | No |
| Moradi et al. ( 30 ) | 0/231 | ----- | PCR | No |
| Eslamifar et al. ( 28 ) | 0/100 | 0/50 | Nested PCR | No |
| Ghaffari et al. ( 25 ) | 20/67 (30%) | - | PCR | Yes (types 16, 11 ⁄ 6, and 31 ⁄ 33) |
| Karimi et al. ( 33 ) | 2/70 | 0/70 | PCR | No |
| Current study | 0/75 | 0/75 | PCR | No |
| Total | 200/1300 (15.3%) | 11/528 (2.08%) | ---- |